Back to top

Image: Bigstock

Encompass Health's (EHC) Nationwide Hospital Count Rises to 147

Read MoreHide Full Article

Encompass Health Corporation (EHC - Free Report) recently inaugurated an inpatient rehabilitation hospital in Illinois named Encompass Health Rehabilitation Institute of Libertyville. The move will enable EHC to better serve Northern Illinois residents by giving them access to high-quality and specialized care in such close proximity to their homes.

When Encompass Health divulged plans of constructing the Libertyville hospital at American Way in June 2020, it had targeted to open the same in the spring of 2022. It is worth mentioning that the healthcare provider has achieved its target as the hospital has opened in March, which marks the beginning of the spring season in the United States.

Equipped with 60 beds, the newly opened Encompass Health Rehabilitation Institute of Libertyville is backed with the much-required rehabilitation equipment and a well-qualified medical expert team. This, in turn, is expected to lead to improved health outcomes for patients availing those services at the hospital.

The latest move strengthens Encompass Health’s capabilities and presence in Illinois further. Apart from the recently inaugurated hospital, EHC has two other inpatient rehabilitation hospitals across the state, one among which (named the Rehabilitation Institute of Southern Illinois) was inaugurated in February 2022. The healthcare provider has plans to open another hospital in the state this year.

The new hospital opening also takes the nationwide inpatient rehabilitation hospital count of Encompass Health to 147. The Inpatient Rehabilitation segment of EHC, which usually contributes the most to the healthcare provider’s top-line growth, continues to benefit from moves like the latest one.

Meanwhile, the dire need for comprehensive rehabilitation services, that helps people recovering from chronic illnesses and injuries return to normal daily activities, is expected to enable Encompass Health with a robust healthcare suite capitalize on the prevailing scenario. Also, effective rehabilitation services are of immense importance throughout the world as they can reduce the harmful impacts of chronic health conditions to some extent. Per the World Health Organization, around 2.4 billion people around the globe are presently surviving with a health condition, which benefits from rehabilitation.

Encompass Health has left no stone unturned in delving deep across every corner of the United States grappling with inadequate access to quality care. For complementing this endeavor, EHC has continuously laid plans for constructing inpatient rehabilitation hospitals equipped with advanced rehabilitation technologies and within a targeted time period, the construction gets completed and the hospitals start operating. What remains noteworthy is the several uncertainties inflicted by the COVID-19 pandemic, which otherwise puts a strain on the financial position of healthcare providers to pursue expansion initiatives, failed to do so for Encompass Health. The last two years in which the ill effects of the pandemic were mostly felt, has been quite an active year for EHC with respect to expansion endeavors.

Shares of Encompass Health have gained 6.4% year to date against the industry’s decline of 8.7%.

Zacks Investment Research
Image Source: Zacks Investment Research

EHC currently has a Zacks Rank #4 (Sell).

Stocks to Consider

Some better-ranked stocks in the medical space are Applied Therapeutics, Inc. (APLT - Free Report) , Quidel Corporation (QDEL - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . While Quidel sports a Zacks Rank #1 (Strong Buy), Applied Therapeutics and IDEXX Laboratories carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Applied Therapeutics delivered a trailing four-quarter earnings surprise of 2.58%, on average. The Zacks Consensus Estimate for APLT’s 2022 earnings suggests an improvement of 17.7% from the year-ago reported figure. The consensus mark for Applied Therapeutics' 2022 earnings has moved north by 11.9% in the past 30 days. 

Quidel delivered a trailing four-quarter earnings surprise of 129.40%, on average. The Zacks Consensus Estimate for QDEL’s 2022 earnings has moved north by 105.1% in the past 60 days. Quidel has a Value Score of B.

IDEXX Laboratories outpaced earnings estimates in each of the last four quarters, the average surprise being 18.55%. The Zacks Consensus Estimate for IDXX’s 2022 earnings indicates a rise of 9.9% year over year, while the same for revenues suggests an improvement of 10.3%. The consensus mark has moved north by 1.1% in the past 60 days. IDEXX Laboratories has a Growth Score of B.

Shares of Applied Therapeutics, Quidel and IDEXX Laboratories have lost 77.2%, 15.6% and 17%, respectively, year to date.

Published in